参蛭通心胶囊治疗气虚血瘀型房颤合并心衰的临床研究

发布时间：2018-05-25 15:13

本文选题：气虚血瘀 + 心房颤动　；参考：《山东中医药大学》2016年硕士论文

【摘要】：目的:观察参蛭通心胶囊治疗气虚血瘀型房颤的临床疗效,同时探讨其对心功能的影响,为治疗房颤和提高患者的生存质量提供新的临床依据。方法:选择气虚血瘀型房颤合并心衰的患者60例,随机分成治疗组和对照组各30例,对照组给予西药常规治疗,治疗组在常规治疗的基础上给予中药参蛭通心胶囊,观察4周后,记录并分析比较两组患者治疗后的临床疗效。结果:治疗后,治疗组房颤转复率为80%,对照组为70%,治疗组高于对照组;治疗组患者的房颤相关症状明显改善(P0.05);治疗组可显著改善患者心功能(P0.05);治疗组在降低血NT-proBNP、Hs-CRP水平和减小左房内径,提高射血分数方面明显优于对照组(P0.05);两组患者24小时平均心室率均明显降低,但治疗组显著优于对照组(P0.05);两组患者的24小时总心搏数均显著降低(P0.01)。在改善中医症状方面,治疗组总有效率为90%,对照组总有效率为73.33%,两组比较差异明显(P0.05),有统计学意义。结论:参蛭通心胶囊可提高房颤的转复率,降低房颤发作次数和改善患者的房颤症状和心功能,对于房颤合并心衰的患者有确切的疗效。
[Abstract]:Objective: to observe the clinical effect of Shenzhi Tongxin capsule on atrial fibrillation due to qi deficiency and blood stasis, and to explore the effect of Shenzhi Tongxin capsule on cardiac function so as to provide a new clinical basis for the treatment of atrial fibrillation and the improvement of patients' quality of life. Methods: sixty patients with atrial fibrillation complicated with heart failure were randomly divided into treatment group (n = 30) and control group (n = 30). The control group was treated with routine western medicine, and the treatment group was treated with Shenzhi Tongxin capsule on the basis of routine treatment. After 4 weeks of observation, the clinical effects of the two groups were recorded and analyzed. Results: after treatment, the conversion rate of atrial fibrillation was 80 in the treatment group and 70 in the control group, which was higher in the treatment group than in the control group. The symptoms associated with atrial fibrillation in the treatment group were significantly improved (P 0.05), the heart function in the treatment group was significantly improved (P 0.05), the serum NT-proBNPN Hs-CRP level and the left atrial diameter were decreased in the treatment group. The increase of ejection fraction was significantly better than that of the control group (P 0.05), the mean 24 hour ventricular rate in both groups was significantly lower than that in the control group, but the treatment group was significantly better than that in the control group (P 0.05), and the 24 hour total cardiac beats in both groups were significantly lower than that in the control group (P 0.01). The total effective rate was 90 in the treatment group and 73.33 in the control group. The difference between the two groups was significant (P 0.05). Conclusion: Shenzhi Tongxin capsule can improve the conversion rate of atrial fibrillation, reduce the frequency of atrial fibrillation attack and improve the symptoms of atrial fibrillation and cardiac function. It is effective for patients with atrial fibrillation complicated with heart failure.
【学位授予单位】：山东中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R259

【参考文献】